Palatin Technologies (PTN) Reports In-Line Q3 EPS

Go back to Palatin Technologies (PTN) Reports In-Line Q3 EPS

Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

May 17, 2022 7:30 AM EDT

Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calendar 2022Vyleesi® - Gross product sales increased 67%, net product revenue increased 200% and prescriptions dispensed increased 20%, over the prior quarterClosed on a $15 Million Private Placement of Convertible Redeemable Preferred Stock Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Expected to Start Next Month with Topline Results Currently Expected First Quarter Calendar 2023Teleconference and Webcast to be held on May 17, 2022 at 11:00 AM... More